Meet
Brigit Kyei-Baffour

Brigit Kyei-Baffour advises clients on issues related to reimbursement, policy, and market access strategies for diagnostic, medical device, and pharmaceutical companies.

She leverages her experience analyzing Medicare and commercial payer policies, supporting health systems with the implementation of bundled payment initiatives, and providing market access support for pharmaceutical and medical device companies.

Prior to joining Avalere, Brigit worked at The Lewin Group where she managed project tasks related to Medicare’s Comprehensive Care for Joint Replacement Model and Bundled Payments for Care Improvement Initiative and led the development of several outcomes-based quality measures. Prior, she held consulting roles in the Access and Commercial Strategy practice at Covance Market Access Services, Inc., where she conducted in-depth health policy analyses related to coverage and reimbursement issues within the commercial and public payer spaces.

Brigit holds an MBA in health management and policy from the George Washington University School of Business and a BS in economics from the Wharton School of the University of Pennsylvania.

Authored Content


In light of proposed changes to the ESRD Treatment Choices Model to address health disparities, an Avalere analysis of Medicare claims found gaps in access to and utilization of specific dialysis-related services by patient race, ethnicity, and socioeconomic status.

Reducing health disparities is critical to advancing health equity, and each stakeholder has a role to play.

Digital health solutions continue to advance the way healthcare is delivered. Through research and development as well as stakeholder partnerships, life science companies can leverage digital health technologies to optimize access along the patient care journey.

Manufacturers seeking Food & Drug Administration (FDA) approval for cell therapies will need to assess the financial and logistical burden on patients and develop novel solutions to help alleviate these challenges.

Tune into the second segment of the Avalere Health Essential Voice series focused on disease education. In this segment, experts from our Market Access practice discuss rare disease patient support programs and the need for stakeholder partnerships to address many of the barriers patients and their caregivers face.

Tune into the second segment of the Avalere Health Essential Voice podcast series focused on disease education. In this segment, experts from our Market Access practice discuss rare disease patient support programs and the need for stakeholder partnerships to address many of the barriers patients and their caregivers face.

Type 2 diabetes (T2D) rates have grown substantially over the years and have placed a significant burden on the US healthcare system. While prevention efforts continue to advance, including the availability of screening tools and early prevention therapies, systemic disparities still preclude equitable access to preventive services. These will need to be addressed as a key component of strengthening patient access to preventive care and lowering the incidence of disease.

With a number of cell and gene therapies (CGTs) expected to obtain Food & Drug Administration (FDA) approval in the next 3 years, stakeholders must consider the unique patient access and affordability barriers that may limit patient ability to receive these novel treatments. Stakeholders should explore affordability solutions that can optimize access, or they risk excluding patients from obtaining potentially life-saving treatments.

Tune into our second episode in the Avalere Health Essential Voice podcast series focused on social determinants of health (SDOH). In this segment, Avalere experts from the Center for Healthcare Transformation and Market Access practices discuss the strategies for SDOH solutions, specifically in the manufacturer space.

As the economic and social impact of COVID-19 change how patients access and receive care, manufacturers and third-party suppliers must consider how to evolve their patient support programs to meet the shifting access and affordability needs of patients.

Tune in to hear the first episode in our 3-part series that focuses on CMS’s most recent proposed payment rules. In episode 1, we’ll be focusing on the outpatient prospective payment system proposed rule, more informally known as the OPPS.

Avalere experts published a supplement in the June 2019 American Journal of Managed Care entitled “Ensuring Appropriate Access to Pulmonary Arterial Hypertension Therapy.”

Recent developments in the specialty pharmaceutical marketplace merit distinct attention from manufacturers.

Beginning in 2019, CMS will reimburse for 5 codes relating to virtual care delivery and remote monitoring